Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time
- PMID: 9184403
Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time
Abstract
The use of recombinant (r) hirudin as an anticoagulant in performing extracorporeal circulation systems including cardiopulmonary bypass (CPB) devices requires a specific and easy to handle monitoring system. The usefulness of the celite-induced activated clotting time (ACT) and the activated partial thromboplastin time (APTT) for r-hirudin monitoring has been tested on ex vivo blood samples obtained from eight patients treated with r-hirudin during open heart surgery. The very poor relationship between the prolongation of the ACT and APTT values and the concentration of r-hirudin as measured using a chromogenic factor IIa assay indicates that both assays are not suitable to monitor r-hirudin anticoagulation. As an alternative approach a whole blood clotting assay based on the prothrombin-activating snake venom ecarin has been tested. In vitro experiments using r-hirudin-spiked whole blood samples showed a linear relationship between the concentration of hirudin added and the prolongation of the clotting times up to a concentration of r-hirudin of 4.0 micrograms/ml. Interassay coefficients (CV) of variation between 2.1% and 5.4% demonstrate the accuracy of the ecarin clotting time (ECT) assay. Differences in the interindividual responsiveness to r-hirudin were analyzed on r-hirudin-spiked blood samples obtained from 50 healthy blood donors. CV-values between 1.8% and 6% measured at r-hirudin concentrations between 0.5 and 4 micrograms/ml indicate remarkably slight differences in r-hirudin responsiveness. ECT assay results of the ex vivo blood samples linearily correlate (r = 0.79) to the concentration of r-hirudin. Moreover, assay results were not influenced by treatment with aprotinin or heparin. These findings together with the short measuring time with less than 120 seconds warrant the whole blood ECT to be a suitable assay for monitoring of r-hirudin anticoagulation in cardiac surgery.
Similar articles
-
[Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].Ann Biol Clin (Paris). 2005 Mar-Apr;63(2):201-8. Ann Biol Clin (Paris). 2005. PMID: 15771978 French.
-
Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.Am J Clin Pathol. 2006 Feb;125(2):290-5. doi: 10.1309/0TDG-8BEC-LWCB-XCDK. Am J Clin Pathol. 2006. PMID: 16393689
-
Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.Thromb Res. 1997 Jun 1;86(5):373-83. doi: 10.1016/s0049-3848(97)00082-0. Thromb Res. 1997. PMID: 9211628
-
[Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].Ann Biol Clin (Paris). 2000 Sep-Oct;58(5):575-9. Ann Biol Clin (Paris). 2000. PMID: 11022100 Review. French.
-
Hirudin in renal insufficiency.Semin Thromb Hemost. 2002 Oct;28(5):467-82. doi: 10.1055/s-2002-35288. Semin Thromb Hemost. 2002. PMID: 12420243 Review.
Cited by
-
Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.Br J Clin Pharmacol. 2001 Jan;51(1):71-9. doi: 10.1046/j.1365-2125.2001.01326.x. Br J Clin Pharmacol. 2001. PMID: 11167667 Free PMC article. Clinical Trial.
-
Benefit-risk assessment of treatments for heparin-induced thrombocytopenia.Drug Saf. 2003;26(9):625-41. doi: 10.2165/00002018-200326090-00003. Drug Saf. 2003. PMID: 12814331 Review.
-
Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.J Thromb Thrombolysis. 2000 Nov;10 Suppl 1:47-57. doi: 10.1023/a:1027333320023. J Thromb Thrombolysis. 2000. PMID: 11155194 Review. No abstract available.
-
Bilateral renal artery thrombosis due to heparin-induced thrombocytopenia-thrombosis syndrome. Successful treatment with longterm application of lepirudin.Ulster Med J. 2006 Jan;75(1):88-90. Ulster Med J. 2006. PMID: 16457411 Free PMC article. No abstract available.
-
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?Molecules. 2016 Feb 27;21(3):284. doi: 10.3390/molecules21030284. Molecules. 2016. PMID: 26927051 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials